GlassScriptPhysician profile
Serge Khelemsky
NPI 1528405420
$4,694.46
in general payments reported to CMS, 2019-2025
33 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $250 · 2021: $293 · 2022: $760 · 2023: $983 · 2024: $1,096 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,208 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.92 |
| Education | $183.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.49 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $629.23 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $346.48 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $257.56 | 2022 | |
| Neurocrine Biosciences, INC. | $254.52 | 2020-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $215.85 | 2020-2025 | Crexont, Rytary, Ongentys |
| Lilly USA, LLC | $178.57 | 2020-2025 | Emgality, Reyvow |
| Lundbeck LLC | $172.89 | 2023-2025 | Vyepti, Rexulti |
| Scilex Pharmaceuticals INC. | $162.52 | 2020-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $134.49 | 2021 | |
| Biogen, INC. | $131.57 | 2020-2025 | Tysabri, Vumerity, Leqembi |
| Amgen INC. | $130.32 | 2022-2025 | Aimovig, Uplizna |
| Otsuka America Pharmaceutical, INC. | $123.47 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $101.66 | 2022-2023 | Quviviq |
| Eisai INC. | $82.54 | 2020-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $69.54 | 2021-2022 | |
| Axsome Therapeutics, INC. | $54.61 | 2023-2025 | Symbravo, Auvelity |
| Abbott Laboratories | $54.36 | 2021-2024 | Infinity |
| Acadia Pharmaceuticals INC | $50.08 | 2023-2024 | Nuplazid |
| Ipsen Biopharmaceuticals, INC | $42.62 | 2023-2025 | Dysport |
| Celgene Corporation | $41.95 | 2024 | Zeposia |
| Medtronic, INC. | $40.84 | 2025 | Percept PC Brainsense |
| Merck Sharp & Dohme LLC | $37.59 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.51 | 2023-2024 | |
| Ucb, INC. | $27.36 | 2023 | Nayzilam |
| Argenx US, INC. | $27.35 | 2025 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $26.87 | 2024 | Xeomin |
| Harmony Biosciences LLC | $25.39 | 2020 | |
| Vanda Pharmaceuticals INC. | $24.99 | 2025 | Ponvory |
| Sk Life Science, INC. | $23.08 | 2020 | |
| Genzyme Corporation | $21.10 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.97 | 2024 | Horizant |
| Alnylam Pharmaceuticals INC. | $15.09 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serge Khelemsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.